Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report)'s share price crossed below its 50 day moving average during trading on Thursday following insider selling activity. The stock has a 50 day moving average of $41.23 and traded as low as $40.21. Edgewise Therapeutics shares last traded at $41.1260, with a volume of 1,193,955 shares traded.
Specifically, CMO Joanne Donovan sold 854 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $45.48, for a total transaction of $38,839.92. Following the completion of the transaction, the chief marketing officer directly owned 8,139 shares of the company's stock, valued at $370,161.72. This represents a 9.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Analysts Set New Price Targets
Several brokerages have recently commented on EWTX. William Blair initiated coverage on Edgewise Therapeutics in a research note on Friday, October 16th. They set an "outperform" rating on the stock. Raymond James Financial reaffirmed an "underperform" rating and issued a $85.00 price objective on shares of Edgewise Therapeutics in a research note on Thursday, November 5th. The Goldman Sachs Group lifted their price objective on Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Wall Street Zen upgraded Edgewise Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, October 4th. Finally, HC Wainwright reissued a "buy" rating on shares of Edgewise Therapeutics in a report on Wednesday, October 14th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Edgewise Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $52.83.
View Our Latest Stock Report on Edgewise Therapeutics
Edgewise Therapeutics Stock Performance
The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of 5.02 and a beta of 0.39. The firm has a fifty day moving average of $41.23 and a 200-day moving average of $37.26.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $9.65 EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $10.18. On average, analysts predict that Edgewise Therapeutics, Inc. will post 9.11 EPS for the current year.
Institutional Trading of Edgewise Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its position in Edgewise Therapeutics by 64.9% during the 1st quarter. Parallel Advisors LLC now owns 1,032 shares of the company's stock worth $33,000 after acquiring an additional 406 shares during the period. Allworth Financial LP increased its holdings in shares of Edgewise Therapeutics by 389.8% during the third quarter. Allworth Financial LP now owns 862 shares of the company's stock valued at $35,000 after purchasing an additional 686 shares during the period. KBC Group NV bought a new stake in shares of Edgewise Therapeutics during the first quarter valued at about $49,000. Steward Partners Investment Advisory LLC raised its stake in shares of Edgewise Therapeutics by 49.4% during the third quarter. Steward Partners Investment Advisory LLC now owns 1,814 shares of the company's stock valued at $74,000 after purchasing an additional 600 shares in the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of Edgewise Therapeutics by 840.2% during the third quarter. Sterling Capital Management LLC now owns 2,360 shares of the company's stock valued at $96,000 after purchasing an additional 2,109 shares in the last quarter.
About Edgewise Therapeutics
(
Get Free Report)
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.